JP2006521793A - Ｅｇｆｒインヒビター薬物に応答性の遺伝子発現マーカー - Google Patents
Ｅｇｆｒインヒビター薬物に応答性の遺伝子発現マーカー Download PDFInfo
- Publication number
- JP2006521793A JP2006521793A JP2006503407A JP2006503407A JP2006521793A JP 2006521793 A JP2006521793 A JP 2006521793A JP 2006503407 A JP2006503407 A JP 2006503407A JP 2006503407 A JP2006503407 A JP 2006503407A JP 2006521793 A JP2006521793 A JP 2006521793A
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- expression
- gene
- patient
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000014509 gene expression Effects 0.000 title claims abstract description 119
- 229940121647 egfr inhibitor Drugs 0.000 title claims abstract description 34
- 239000003814 drug Substances 0.000 title description 18
- 229940079593 drug Drugs 0.000 title description 15
- 239000003550 marker Substances 0.000 title description 3
- 238000000034 method Methods 0.000 claims abstract description 108
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 92
- 238000011282 treatment Methods 0.000 claims abstract description 60
- 201000011510 cancer Diseases 0.000 claims abstract description 48
- 108090000623 proteins and genes Proteins 0.000 claims description 88
- 239000000523 sample Substances 0.000 claims description 51
- -1 CCAP4 Proteins 0.000 claims description 36
- 238000003752 polymerase chain reaction Methods 0.000 claims description 25
- 102000040430 polynucleotide Human genes 0.000 claims description 23
- 108091033319 polynucleotide Proteins 0.000 claims description 23
- 239000002157 polynucleotide Substances 0.000 claims description 22
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 19
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 19
- 101150058731 STAT5A gene Proteins 0.000 claims description 17
- 101150063267 STAT5B gene Proteins 0.000 claims description 17
- 102100024481 Signal transducer and activator of transcription 5A Human genes 0.000 claims description 17
- 108091034117 Oligonucleotide Proteins 0.000 claims description 16
- 238000003757 reverse transcription PCR Methods 0.000 claims description 16
- 102100024474 Signal transducer and activator of transcription 5B Human genes 0.000 claims description 15
- 238000004458 analytical method Methods 0.000 claims description 15
- 206010006187 Breast cancer Diseases 0.000 claims description 14
- 208000026310 Breast neoplasm Diseases 0.000 claims description 14
- 102100031173 CCN family member 4 Human genes 0.000 claims description 14
- 102100023919 Histone H2A.Z Human genes 0.000 claims description 14
- 101000777560 Homo sapiens CCN family member 4 Proteins 0.000 claims description 14
- 101000905054 Homo sapiens Histone H2A.Z Proteins 0.000 claims description 14
- 101000979629 Homo sapiens Nucleoside diphosphate kinase A Proteins 0.000 claims description 14
- 101000712958 Homo sapiens Ras association domain-containing protein 1 Proteins 0.000 claims description 14
- 102100023252 Nucleoside diphosphate kinase A Human genes 0.000 claims description 14
- 102100033243 Ras association domain-containing protein 1 Human genes 0.000 claims description 14
- 239000002299 complementary DNA Substances 0.000 claims description 14
- YPSXFMHXRZAGTG-UHFFFAOYSA-N 4-methoxy-2-[2-(5-methoxy-2-nitrosophenyl)ethyl]-1-nitrosobenzene Chemical compound COC1=CC=C(N=O)C(CCC=2C(=CC=C(OC)C=2)N=O)=C1 YPSXFMHXRZAGTG-UHFFFAOYSA-N 0.000 claims description 13
- 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 claims description 13
- 102100032912 CD44 antigen Human genes 0.000 claims description 13
- 102100033189 Diablo IAP-binding mitochondrial protein Human genes 0.000 claims description 13
- 101000971171 Homo sapiens Apoptosis regulator Bcl-2 Proteins 0.000 claims description 13
- 101000868273 Homo sapiens CD44 antigen Proteins 0.000 claims description 13
- 101000871228 Homo sapiens Diablo IAP-binding mitochondrial protein Proteins 0.000 claims description 13
- 101001034652 Homo sapiens Insulin-like growth factor 1 receptor Proteins 0.000 claims description 13
- 101000645296 Homo sapiens Metalloproteinase inhibitor 2 Proteins 0.000 claims description 13
- 101000652736 Homo sapiens Transgelin Proteins 0.000 claims description 13
- 102100039688 Insulin-like growth factor 1 receptor Human genes 0.000 claims description 13
- 102100026262 Metalloproteinase inhibitor 2 Human genes 0.000 claims description 13
- 102000048238 Neuregulin-1 Human genes 0.000 claims description 13
- 108090000556 Neuregulin-1 Proteins 0.000 claims description 13
- 101150001535 SRC gene Proteins 0.000 claims description 13
- 102100031013 Transgelin Human genes 0.000 claims description 13
- 101000809450 Homo sapiens Amphiregulin Proteins 0.000 claims description 12
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims description 12
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims description 12
- 102100022224 Y-box-binding protein 1 Human genes 0.000 claims description 12
- 101000823796 Homo sapiens Y-box-binding protein 1 Proteins 0.000 claims description 11
- 238000001574 biopsy Methods 0.000 claims description 11
- 238000010195 expression analysis Methods 0.000 claims description 11
- 108091093088 Amplicon Proteins 0.000 claims description 9
- ZEOWTGPWHLSLOG-UHFFFAOYSA-N Cc1ccc(cc1-c1ccc2c(n[nH]c2c1)-c1cnn(c1)C1CC1)C(=O)Nc1cccc(c1)C(F)(F)F Chemical compound Cc1ccc(cc1-c1ccc2c(n[nH]c2c1)-c1cnn(c1)C1CC1)C(=O)Nc1cccc(c1)C(F)(F)F ZEOWTGPWHLSLOG-UHFFFAOYSA-N 0.000 claims description 9
- 101710182386 Fibroblast growth factor receptor 1 Proteins 0.000 claims description 9
- 102100023593 Fibroblast growth factor receptor 1 Human genes 0.000 claims description 9
- 238000003556 assay Methods 0.000 claims description 8
- 201000010536 head and neck cancer Diseases 0.000 claims description 8
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 8
- 238000003364 immunohistochemistry Methods 0.000 claims description 8
- 102100038778 Amphiregulin Human genes 0.000 claims description 7
- 102000004989 Hepsin Human genes 0.000 claims description 7
- 108090001101 Hepsin Proteins 0.000 claims description 7
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 claims description 7
- 238000001514 detection method Methods 0.000 claims description 7
- 206010009944 Colon cancer Diseases 0.000 claims description 6
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 6
- 208000029742 colonic neoplasm Diseases 0.000 claims description 6
- 201000005202 lung cancer Diseases 0.000 claims description 6
- 208000020816 lung neoplasm Diseases 0.000 claims description 6
- 230000002018 overexpression Effects 0.000 claims description 6
- 108700039887 Essential Genes Proteins 0.000 claims description 5
- 206010033128 Ovarian cancer Diseases 0.000 claims description 5
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 5
- 238000004445 quantitative analysis Methods 0.000 claims description 5
- 230000002829 reductive effect Effects 0.000 claims description 5
- 102100021633 Cathepsin B Human genes 0.000 claims description 4
- 101000898449 Homo sapiens Cathepsin B Proteins 0.000 claims description 4
- 101150038994 PDGFRA gene Proteins 0.000 claims description 4
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 4
- 239000003153 chemical reaction reagent Substances 0.000 claims description 4
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 4
- 201000002528 pancreatic cancer Diseases 0.000 claims description 4
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 4
- 238000010839 reverse transcription Methods 0.000 claims description 4
- 239000007787 solid Substances 0.000 claims description 4
- 101000692455 Homo sapiens Platelet-derived growth factor receptor beta Proteins 0.000 claims description 3
- 101150093908 PDGFRB gene Proteins 0.000 claims description 3
- 102100026547 Platelet-derived growth factor receptor beta Human genes 0.000 claims description 3
- 238000011529 RT qPCR Methods 0.000 claims description 3
- 239000000872 buffer Substances 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 238000013188 needle biopsy Methods 0.000 claims description 3
- 239000012188 paraffin wax Substances 0.000 claims description 3
- 238000011277 treatment modality Methods 0.000 claims description 3
- 108010085238 Actins Proteins 0.000 claims description 2
- 102100028629 Cytoskeleton-associated protein 4 Human genes 0.000 claims description 2
- 101000766853 Homo sapiens Cytoskeleton-associated protein 4 Proteins 0.000 claims description 2
- 101001027925 Homo sapiens Metastasis-associated protein MTA1 Proteins 0.000 claims description 2
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims description 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims description 2
- 108010014691 Lithostathine Proteins 0.000 claims description 2
- 102100027361 Lithostathine-1-alpha Human genes 0.000 claims description 2
- 102100037517 Metastasis-associated protein MTA1 Human genes 0.000 claims description 2
- 108010048626 Y-Box-Binding Protein 1 Proteins 0.000 claims description 2
- 239000011521 glass Substances 0.000 claims description 2
- 150000003384 small molecules Chemical group 0.000 claims description 2
- 101100069822 Drosophila melanogaster gus gene Proteins 0.000 claims 7
- 101150001754 Gusb gene Proteins 0.000 claims 7
- 101001126417 Homo sapiens Platelet-derived growth factor receptor alpha Proteins 0.000 claims 2
- 102100030485 Platelet-derived growth factor receptor alpha Human genes 0.000 claims 2
- 102000006602 glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 claims 2
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 claims 2
- 102000007469 Actins Human genes 0.000 claims 1
- 108010088751 Albumins Proteins 0.000 claims 1
- 102000009027 Albumins Human genes 0.000 claims 1
- 102000001493 Cyclophilins Human genes 0.000 claims 1
- 108010068682 Cyclophilins Proteins 0.000 claims 1
- 102000018251 Hypoxanthine Phosphoribosyltransferase Human genes 0.000 claims 1
- 108010091358 Hypoxanthine Phosphoribosyltransferase Proteins 0.000 claims 1
- 108090000704 Tubulin Proteins 0.000 claims 1
- 102000004243 Tubulin Human genes 0.000 claims 1
- 239000011536 extraction buffer Substances 0.000 claims 1
- 238000005259 measurement Methods 0.000 claims 1
- 238000012512 characterization method Methods 0.000 abstract description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 56
- 210000001519 tissue Anatomy 0.000 description 51
- 108020004414 DNA Proteins 0.000 description 29
- 230000004044 response Effects 0.000 description 23
- 108020004999 messenger RNA Proteins 0.000 description 20
- 210000004027 cell Anatomy 0.000 description 18
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 17
- 102000001301 EGF receptor Human genes 0.000 description 15
- 108060006698 EGF receptor Proteins 0.000 description 15
- 201000010099 disease Diseases 0.000 description 13
- 230000003321 amplification Effects 0.000 description 11
- 238000009396 hybridization Methods 0.000 description 11
- 238000003199 nucleic acid amplification method Methods 0.000 description 11
- 102000004169 proteins and genes Human genes 0.000 description 11
- 238000006243 chemical reaction Methods 0.000 description 10
- 230000000875 corresponding effect Effects 0.000 description 10
- 239000013615 primer Substances 0.000 description 9
- 210000004881 tumor cell Anatomy 0.000 description 9
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- 230000008901 benefit Effects 0.000 description 8
- 238000012163 sequencing technique Methods 0.000 description 7
- 102000053602 DNA Human genes 0.000 description 6
- 239000000975 dye Substances 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 238000010606 normalization Methods 0.000 description 6
- 239000011325 microbead Substances 0.000 description 5
- 230000036961 partial effect Effects 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 238000000746 purification Methods 0.000 description 5
- 102100031780 Endonuclease Human genes 0.000 description 4
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 4
- 108010006785 Taq Polymerase Proteins 0.000 description 4
- 238000004113 cell culture Methods 0.000 description 4
- 238000002512 chemotherapy Methods 0.000 description 4
- 230000009274 differential gene expression Effects 0.000 description 4
- 208000035475 disorder Diseases 0.000 description 4
- AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 description 4
- 239000007850 fluorescent dye Substances 0.000 description 4
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 description 4
- 238000011223 gene expression profiling Methods 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 238000010841 mRNA extraction Methods 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 238000002493 microarray Methods 0.000 description 4
- 238000012775 microarray technology Methods 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 230000002441 reversible effect Effects 0.000 description 4
- 230000035945 sensitivity Effects 0.000 description 4
- 238000003196 serial analysis of gene expression Methods 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 239000001509 sodium citrate Substances 0.000 description 4
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- 238000001356 surgical procedure Methods 0.000 description 4
- 230000004083 survival effect Effects 0.000 description 4
- 239000005411 L01XE02 - Gefitinib Substances 0.000 description 3
- 239000005551 L01XE03 - Erlotinib Substances 0.000 description 3
- 206010027476 Metastases Diseases 0.000 description 3
- 101710163270 Nuclease Proteins 0.000 description 3
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 3
- 108020004682 Single-Stranded DNA Proteins 0.000 description 3
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 3
- 210000004102 animal cell Anatomy 0.000 description 3
- 230000002860 competitive effect Effects 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 230000009401 metastasis Effects 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 238000011002 quantification Methods 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 238000011269 treatment regimen Methods 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 2
- 241000972773 Aulopiformes Species 0.000 description 2
- 239000003298 DNA probe Substances 0.000 description 2
- 101150029707 ERBB2 gene Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 238000012408 PCR amplification Methods 0.000 description 2
- 238000010802 RNA extraction kit Methods 0.000 description 2
- 108091028664 Ribonucleotide Proteins 0.000 description 2
- 238000000692 Student's t-test Methods 0.000 description 2
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 230000000692 anti-sense effect Effects 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 229960000633 dextran sulfate Drugs 0.000 description 2
- 238000002405 diagnostic procedure Methods 0.000 description 2
- 229960001433 erlotinib Drugs 0.000 description 2
- 102000015694 estrogen receptors Human genes 0.000 description 2
- 108010038795 estrogen receptors Proteins 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 229960002584 gefitinib Drugs 0.000 description 2
- 238000007901 in situ hybridization Methods 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 229940084651 iressa Drugs 0.000 description 2
- 230000003211 malignant effect Effects 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 238000009522 phase III clinical trial Methods 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 230000000171 quenching effect Effects 0.000 description 2
- 230000008439 repair process Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000002336 ribonucleotide Substances 0.000 description 2
- 125000002652 ribonucleotide group Chemical group 0.000 description 2
- 235000019515 salmon Nutrition 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000001488 sodium phosphate Substances 0.000 description 2
- 229910000162 sodium phosphate Inorganic materials 0.000 description 2
- 238000011272 standard treatment Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000012353 t test Methods 0.000 description 2
- 229940120982 tarceva Drugs 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 2
- 230000004614 tumor growth Effects 0.000 description 2
- RUCIIQOYYLOGEI-UHFFFAOYSA-N 2-methyl-N-[2-(trifluoromethoxy)phenyl]prop-2-enamide Chemical compound CC(C(=O)NC1=C(C=CC=C1)OC(F)(F)F)=C RUCIIQOYYLOGEI-UHFFFAOYSA-N 0.000 description 1
- 102100022900 Actin, cytoplasmic 1 Human genes 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 101150002885 Avil gene Proteins 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 230000004544 DNA amplification Effects 0.000 description 1
- 239000003155 DNA primer Substances 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 108010042407 Endonucleases Proteins 0.000 description 1
- 108010043939 Ephrin-A5 Proteins 0.000 description 1
- 229920001917 Ficoll Polymers 0.000 description 1
- 102000009465 Growth Factor Receptors Human genes 0.000 description 1
- 108010009202 Growth Factor Receptors Proteins 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 229930010555 Inosine Natural products 0.000 description 1
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- 241000713869 Moloney murine leukemia virus Species 0.000 description 1
- 238000000636 Northern blotting Methods 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 238000009004 PCR Kit Methods 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 108010026552 Proteome Proteins 0.000 description 1
- 238000002123 RNA extraction Methods 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 208000024770 Thyroid neoplasm Diseases 0.000 description 1
- 108010020713 Tth polymerase Proteins 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 208000006593 Urologic Neoplasms Diseases 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000012491 analyte Substances 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 229940046836 anti-estrogen Drugs 0.000 description 1
- 230000001833 anti-estrogenic effect Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 230000005975 antitumor immune response Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000004709 cell invasion Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 229960005395 cetuximab Drugs 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 239000003398 denaturant Substances 0.000 description 1
- 238000000432 density-gradient centrifugation Methods 0.000 description 1
- 239000005547 deoxyribonucleotide Substances 0.000 description 1
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 239000000328 estrogen antagonist Substances 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000005713 exacerbation Effects 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 230000004547 gene signature Effects 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- 229940022353 herceptin Drugs 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 229960003786 inosine Drugs 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 238000010208 microarray analysis Methods 0.000 description 1
- 210000005170 neoplastic cell Anatomy 0.000 description 1
- 230000009826 neoplastic cell growth Effects 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- VZORGPCQYCYZLZ-UHFFFAOYSA-E nonasodium;2-hydroxypropane-1,2,3-tricarboxylate Chemical compound [Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O VZORGPCQYCYZLZ-UHFFFAOYSA-E 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 238000002515 oligonucleotide synthesis Methods 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 238000009521 phase II clinical trial Methods 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 208000037821 progressive disease Diseases 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001915 proofreading effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 238000000575 proteomic method Methods 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- JWVCLYRUEFBMGU-UHFFFAOYSA-N quinazoline Chemical compound N1=CN=CC2=CC=CC=C21 JWVCLYRUEFBMGU-UHFFFAOYSA-N 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 102000027426 receptor tyrosine kinases Human genes 0.000 description 1
- 108091008598 receptor tyrosine kinases Proteins 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 238000007670 refining Methods 0.000 description 1
- 238000012340 reverse transcriptase PCR Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000005204 segregation Methods 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- FQENQNTWSFEDLI-UHFFFAOYSA-J sodium diphosphate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]P([O-])(=O)OP([O-])([O-])=O FQENQNTWSFEDLI-UHFFFAOYSA-J 0.000 description 1
- 239000012064 sodium phosphate buffer Substances 0.000 description 1
- 229940048086 sodium pyrophosphate Drugs 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 229960001603 tamoxifen Drugs 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 235000019818 tetrasodium diphosphate Nutrition 0.000 description 1
- 239000001577 tetrasodium phosphonato phosphate Substances 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 201000002510 thyroid cancer Diseases 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 230000005748 tumor development Effects 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Hospice & Palliative Care (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Oncology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US44596803P | 2003-02-06 | 2003-02-06 | |
| PCT/US2004/003596 WO2004071572A2 (en) | 2003-02-06 | 2004-02-05 | Gene expression markers for response to egfr inhibitor drugs |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2006521793A true JP2006521793A (ja) | 2006-09-28 |
| JP2006521793A5 JP2006521793A5 (https=) | 2007-03-22 |
Family
ID=32869443
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006503407A Pending JP2006521793A (ja) | 2003-02-06 | 2004-02-05 | Ｅｇｆｒインヒビター薬物に応答性の遺伝子発現マーカー |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US20040157255A1 (https=) |
| EP (1) | EP1590487A2 (https=) |
| JP (1) | JP2006521793A (https=) |
| AU (2) | AU2004211955B2 (https=) |
| CA (1) | CA2515096A1 (https=) |
| WO (1) | WO2004071572A2 (https=) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010064702A1 (ja) * | 2008-12-05 | 2010-06-10 | 国立大学法人 東京大学 | 癌の予後を予測するためのバイオマーカー |
| WO2010084998A1 (en) * | 2009-01-26 | 2010-07-29 | Kyushu University, National University Corporation | A method of predicting the efficacy of a drug |
| JP2014526680A (ja) * | 2011-09-12 | 2014-10-06 | ユニヴェルシテイト ヘント | 結腸直腸ガンのニューレグリン−１に基づく予後予測及び治療層別化 |
| JP2017161531A (ja) * | 2007-10-19 | 2017-09-14 | セル・シグナリング・テクノロジー・インコーポレイテツド | 癌の分類および使用法 |
| KR20180010138A (ko) * | 2016-07-20 | 2018-01-30 | 연세대학교 산학협력단 | 암 예후 예측을 위한 조성물 및 이를 포함하는 키트 |
Families Citing this family (54)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050059012A1 (en) * | 2002-07-31 | 2005-03-17 | Daniel Afar | Diagnosis of ZD1839 resistant tumors |
| US7483554B2 (en) * | 2003-11-17 | 2009-01-27 | Aureon Laboratories, Inc. | Pathological tissue mapping |
| US7505948B2 (en) * | 2003-11-18 | 2009-03-17 | Aureon Laboratories, Inc. | Support vector regression for censored data |
| US7467119B2 (en) * | 2003-07-21 | 2008-12-16 | Aureon Laboratories, Inc. | Systems and methods for treating, diagnosing and predicting the occurrence of a medical condition |
| US8017321B2 (en) | 2004-01-23 | 2011-09-13 | The Regents Of The University Of Colorado, A Body Corporate | Gefitinib sensitivity-related gene expression and products and methods related thereto |
| TW200532523A (en) * | 2004-02-27 | 2005-10-01 | Aureon Biosciences Corp | Methods and systems for predicting occurrence of an event |
| WO2005117553A2 (en) | 2004-05-27 | 2005-12-15 | The Regents Of The University Of Colorado | Methods for prediction of clinical outcome to epidermal growth factor receptor inhibitors by cancer patients |
| WO2006020627A1 (en) * | 2004-08-11 | 2006-02-23 | Aureon Laboratories, Inc. | Systems and methods for automated diagnosis and grading of tissue images |
| EP1812589A2 (en) * | 2004-09-30 | 2007-08-01 | Epigenomics AG | Epigenetic methods and nucleic acids for the detection of lung cell proliferative disorders |
| WO2006045991A1 (en) * | 2004-10-25 | 2006-05-04 | Astrazeneca Ab | Method to predict whether a tumor will react to a chemotherapeutic treatment |
| US8383357B2 (en) | 2005-03-16 | 2013-02-26 | OSI Pharmaceuticals, LLC | Biological markers predictive of anti-cancer response to epidermal growth factor receptor kinase inhibitors |
| CA2601157A1 (en) | 2005-03-16 | 2006-09-28 | Osi Pharmaceuticals, Inc. | Biological markers predictive of anti-cancer response to epidermal growth factor receptor kinase inhibitors |
| AR053272A1 (es) | 2005-05-11 | 2007-04-25 | Hoffmann La Roche | Determinacion de responsivos a la quimioterapia |
| US7449442B2 (en) * | 2005-07-12 | 2008-11-11 | Children's Medical Center Corporation | EGFR inhibitors promote axon regeneration |
| US7700299B2 (en) * | 2005-08-12 | 2010-04-20 | Hoffmann-La Roche Inc. | Method for predicting the response to a treatment |
| ATE520979T1 (de) * | 2005-08-24 | 2011-09-15 | Bristol Myers Squibb Co | Biomarker und verfahren zur bestimmung der empfindlichkeit gegenüber modulatoren des egf(epidermal growth factor)-rezeptors |
| AU2006292278B2 (en) | 2005-09-20 | 2012-03-08 | Osi Pharmaceuticals, Inc. | Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors |
| WO2007067500A2 (en) * | 2005-12-05 | 2007-06-14 | Genomic Health, Inc. | Predictors of patient response to treatment with egfr inhibitors |
| JP2007252312A (ja) * | 2006-03-24 | 2007-10-04 | Japan Health Science Foundation | 上皮成長因子受容体−チロシンキナーゼ阻害剤に対する肺ガンの感度測定方法および肺ガン治療剤のスクリーニング方法 |
| DE102006048249A1 (de) * | 2006-08-10 | 2008-02-14 | Wolff Prof. Dr. Schmiegel | Biomarker für Leberentzündung |
| US20080076134A1 (en) * | 2006-09-21 | 2008-03-27 | Nuclea Biomarkers, Llc | Gene and protein expression profiles associated with the therapeutic efficacy of irinotecan |
| BRPI0717416A2 (pt) | 2006-09-21 | 2013-11-12 | Prometheus Lab Inc | Método para realizar um imunoensaio complexo de alta produtividade, e, arranjo |
| EP2157971B1 (en) * | 2007-04-13 | 2012-01-11 | Rikshospitalet- Radiumhospitalet HF | Egfr inhibitors for treatment and diagnosis of metastatic prostate cancer |
| JP5240739B2 (ja) | 2007-04-13 | 2013-07-17 | オーエスアイ・フアーマシユーテイカルズ・エル・エル・シー | キナーゼ阻害剤に対する抗癌応答を予測する生物学的マーカー |
| ES2526211T3 (es) | 2007-07-13 | 2015-01-08 | Nestec S.A. | Selección de fármacos para la terapia del cáncer de pulmón utilizando matrices basadas en anticuerpos |
| WO2009021680A1 (en) * | 2007-08-14 | 2009-02-19 | F. Hoffmann-La Roche Ag | Predictive marker for egfr inhibitor treatment |
| CN101827947B (zh) * | 2007-08-14 | 2013-11-13 | 霍夫曼-拉罗奇有限公司 | Egfr抑制剂治疗的预测性标记物 |
| MX2010001582A (es) * | 2007-08-14 | 2010-06-02 | Hoffmann La Roche | Marcador predictivo para tratamiento con el inhibidor del receptor del factor de crecimiento epidermico. |
| KR20100037637A (ko) * | 2007-08-14 | 2010-04-09 | 에프. 호프만-라 로슈 아게 | Ｅｇｆｒ 억제제 치료에 대한 예측 마커 |
| JP2010540960A (ja) | 2007-10-03 | 2010-12-24 | オーエスアイ・ファーマスーティカルズ・インコーポレーテッド | インスリン様成長因子−１受容体キナーゼ阻害剤に対する抗癌反応を予測する生物学的マーカー |
| JP2011501660A (ja) | 2007-10-03 | 2011-01-13 | オーエスアイ・ファーマスーティカルズ・インコーポレーテッド | インスリン様成長因子−１受容体キナーゼ阻害剤に対する抗癌反応を予測する生物学的マーカー |
| MX2010005080A (es) | 2007-11-07 | 2010-07-28 | Genentech Inc | Metodos y composiciones para determinar la sensibilidad de linfoma de celula b al tratamiento con anticuerpos anti-cd40. |
| EP2065475A1 (en) * | 2007-11-30 | 2009-06-03 | Siemens Healthcare Diagnostics GmbH | Method for therapy prediction in tumors having irregularities in the expression of at least one VEGF ligand and/or at least one ErbB-receptor |
| NZ617520A (en) | 2008-02-25 | 2015-05-29 | Nestec Sa | Drug selection for breast cancer therapy using antibody-based arrays |
| US8273534B2 (en) * | 2008-05-14 | 2012-09-25 | Genomic Health, Inc. | Predictors of patient response to treatment with EGF receptor inhibitors |
| WO2010015536A1 (en) * | 2008-08-05 | 2010-02-11 | F. Hoffmann-La Roche Ag | Predictive marker for egfr inhibitor treatment |
| KR100996994B1 (ko) * | 2008-08-18 | 2010-11-25 | 울산대학교 산학협력단 | 간세포암종 수술후 재발 또는 재발 발병 위험성의 진단방법 |
| US20110171124A1 (en) * | 2009-02-26 | 2011-07-14 | Osi Pharmaceuticals, Inc. | In situ methods for monitoring the EMT status of tumor cells in vivo |
| KR101787768B1 (ko) | 2009-04-18 | 2017-10-18 | 제넨테크, 인크. | 항-ｃｄ４０ 항체를 사용한 치료에 대한 ｂ-세포 림프종의 반응성 평가를 위한 방법 |
| AU2010273319B2 (en) * | 2009-07-15 | 2015-01-22 | Nestec S.A. | Drug selection for gastric cancer therapy using antibody-based arrays |
| US10731221B2 (en) | 2009-12-11 | 2020-08-04 | Dignity Health | Diagnosing IDH1 related subgroups and treatment of cancer |
| CA2781886A1 (en) * | 2009-12-11 | 2011-06-16 | Dignity Health | Pi3k/akt pathway subgroups in cancer: methods of using biomarkers for diagnosis and therapy |
| CA2783665A1 (en) * | 2010-03-03 | 2011-09-09 | OSI Pharmaceuticals, LLC | Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors |
| CA2783656A1 (en) | 2010-03-03 | 2011-09-09 | OSI Pharmaceuticals, LLC | Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors |
| WO2012097368A2 (en) * | 2011-01-14 | 2012-07-19 | Response Genetics, Inc. | Her3 and her4 primers and probes for detecting her3 and her4 mrna expression |
| US9719995B2 (en) | 2011-02-03 | 2017-08-01 | Pierian Holdings, Inc. | Drug selection for colorectal cancer therapy using receptor tyrosine kinase profiling |
| US20120214830A1 (en) | 2011-02-22 | 2012-08-23 | OSI Pharmaceuticals, LLC | Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors in hepatocellular carcinoma |
| EP2492688A1 (en) | 2011-02-23 | 2012-08-29 | Pangaea Biotech, S.A. | Molecular biomarkers for predicting response to antitumor treatment in lung cancer |
| EP2702173A1 (en) | 2011-04-25 | 2014-03-05 | OSI Pharmaceuticals, LLC | Use of emt gene signatures in cancer drug discovery, diagnostics, and treatment |
| SG2014011316A (en) | 2011-08-31 | 2014-06-27 | Genentech Inc | Diagnostic markers |
| JP6186575B2 (ja) | 2011-09-02 | 2017-08-30 | ダイアテック ホールディングス， インコーポレイテッドＤｉａＴｅｃｈ Ｈｏｌｄｉｎｇｓ， Ｉｎｃ． | 治療有効性を判定するためのシグナル経路タンパク質のプロファイリング |
| JP2014531213A (ja) | 2011-09-30 | 2014-11-27 | ジェネンテック， インコーポレイテッド | 上皮又は間葉の表現型の診断用メチル化マーカー、及び腫瘍又は腫瘍細胞におけるｅｇｆｒキナーゼ阻害薬に対する応答 |
| CN104946597A (zh) * | 2015-03-23 | 2015-09-30 | 大连医科大学附属第一医院 | 稳定表达GFP的shRNA靶向干扰YB-1基因人肺腺癌A549细胞株 |
| CN106680515B (zh) * | 2016-10-21 | 2018-06-12 | 杭州金式麦生物科技有限公司 | 用于肺癌诊断的多分子标志物组合 |
Family Cites Families (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4699877A (en) * | 1982-11-04 | 1987-10-13 | The Regents Of The University Of California | Methods and compositions for detecting human tumors |
| USRE35491E (en) * | 1982-11-04 | 1997-04-08 | The Regents Of The University Of California | Methods and compositions for detecting human tumors |
| US7838216B1 (en) * | 1986-03-05 | 2010-11-23 | The United States Of America, As Represented By The Department Of Health And Human Services | Human gene related to but distinct from EGF receptor gene |
| US5015568A (en) * | 1986-07-09 | 1991-05-14 | The Wistar Institute | Diagnostic methods for detecting lymphomas in humans |
| US5202429A (en) * | 1986-07-09 | 1993-04-13 | The Wistar Institute | DNA molecules having human BCL-2 gene sequences |
| US4968603A (en) * | 1986-12-31 | 1990-11-06 | The Regents Of The University Of California | Determination of status in neoplastic disease |
| US5831066A (en) * | 1988-12-22 | 1998-11-03 | The Trustees Of The University Of Pennsylvania | Regulation of bcl-2 gene expression |
| US5858678A (en) * | 1994-08-02 | 1999-01-12 | St. Louis University | Apoptosis-regulating proteins |
| US5830753A (en) * | 1994-09-30 | 1998-11-03 | Ludwig Institute For Cancer Research | Isolated nucleic acid molecules coding for tumor rejection antigen precursor dage and uses thereof. |
| US6716575B2 (en) * | 1995-12-18 | 2004-04-06 | Sugen, Inc. | Diagnosis and treatment of AUR1 and/or AUR2 related disorders |
| EP1655369A1 (en) * | 1995-12-18 | 2006-05-10 | Sugen, Inc. | Diagnosis and treatment of AUR-1 and/or AUR-2 related disorders |
| US5670325A (en) * | 1996-08-14 | 1997-09-23 | Exact Laboratories, Inc. | Method for the detection of clonal populations of transformed cells in a genomically heterogeneous cellular sample |
| US5741650A (en) * | 1996-01-30 | 1998-04-21 | Exact Laboratories, Inc. | Methods for detecting colon cancer from stool samples |
| US5821082A (en) * | 1996-05-23 | 1998-10-13 | St. Louis University Health Sciences Center | Anti-proliferation domain of a human Bcl-2 and DNA encoding the same |
| US6146828A (en) * | 1996-08-14 | 2000-11-14 | Exact Laboratories, Inc. | Methods for detecting differences in RNA expression levels and uses therefor |
| US6020137A (en) * | 1996-08-14 | 2000-02-01 | Exact Laboratories, Inc. | Methods for the detection of loss of heterozygosity |
| US6203993B1 (en) * | 1996-08-14 | 2001-03-20 | Exact Science Corp. | Methods for the detection of nucleic acids |
| US6143529A (en) * | 1996-08-14 | 2000-11-07 | Exact Laboratories, Inc. | Methods for improving sensitivity and specificity of screening assays |
| US5952178A (en) * | 1996-08-14 | 1999-09-14 | Exact Laboratories | Methods for disease diagnosis from stool samples |
| US6100029A (en) * | 1996-08-14 | 2000-08-08 | Exact Laboratories, Inc. | Methods for the detection of chromosomal aberrations |
| US5928870A (en) * | 1997-06-16 | 1999-07-27 | Exact Laboratories, Inc. | Methods for the detection of loss of heterozygosity |
| US5861278A (en) * | 1996-11-01 | 1999-01-19 | Genetics Institute, Inc. | HNF3δ compositions |
| US6245523B1 (en) * | 1996-11-20 | 2001-06-12 | Yale University | Survivin, a protein that inhibits cellular apoptosis, and its modulation |
| US5830665A (en) * | 1997-03-03 | 1998-11-03 | Exact Laboratories, Inc. | Contiguous genomic sequence scanning |
| US6033893A (en) * | 1997-06-26 | 2000-03-07 | Incyte Pharmaceuticals, Inc. | Human cathepsin |
| US6020135A (en) * | 1998-03-27 | 2000-02-01 | Affymetrix, Inc. | P53-regulated genes |
| GB2339200B (en) * | 1998-06-06 | 2001-09-12 | Genostic Pharma Ltd | Genostics |
| US6696558B2 (en) * | 1998-09-09 | 2004-02-24 | The Burnham Institute | Bag proteins and nucleic acid molecules encoding them |
| US20020039764A1 (en) * | 1999-03-12 | 2002-04-04 | Rosen Craig A. | Nucleic, acids, proteins, and antibodies |
| US6692916B2 (en) * | 1999-06-28 | 2004-02-17 | Source Precision Medicine, Inc. | Systems and methods for characterizing a biological condition or agent using precision gene expression profiles |
| US6960439B2 (en) * | 1999-06-28 | 2005-11-01 | Source Precision Medicine, Inc. | Identification, monitoring and treatment of disease and characterization of biological condition using gene expression profiles |
| US6710170B2 (en) * | 1999-09-10 | 2004-03-23 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of ovarian cancer |
| US6271002B1 (en) * | 1999-10-04 | 2001-08-07 | Rosetta Inpharmatics, Inc. | RNA amplification method |
| US6750013B2 (en) * | 1999-12-02 | 2004-06-15 | Protein Design Labs, Inc. | Methods for detection and diagnosing of breast cancer |
| EP1276901A2 (en) * | 2000-01-13 | 2003-01-22 | Amsterdam Support Diagnostics B.V. | A universal nucleic acid amplification system for nucleic acids in a sample |
| US6322986B1 (en) * | 2000-01-18 | 2001-11-27 | Albany Medical College | Method for colorectal cancer prognosis and treatment selection |
| US6618679B2 (en) * | 2000-01-28 | 2003-09-09 | Althea Technologies, Inc. | Methods for analysis of gene expression |
| US7157227B2 (en) * | 2000-03-31 | 2007-01-02 | University Of Louisville Research Foundation | Microarrays to screen regulatory genes |
| WO2002008461A2 (en) * | 2000-07-21 | 2002-01-31 | Global Genomics Ab | A METHOD AND AN ALGORITHM FOR mRNA EXPRESSION ANALYSIS |
| WO2002024867A2 (en) * | 2000-09-22 | 2002-03-28 | University Of Aarhus | Novel compositions and methods for lymphoma and leukemia |
| US6582919B2 (en) * | 2001-06-11 | 2003-06-24 | Response Genetics, Inc. | Method of determining epidermal growth factor receptor and HER2-neu gene expression and correlation of levels thereof with survival rates |
| US6602670B2 (en) * | 2000-12-01 | 2003-08-05 | Response Genetics, Inc. | Method of determining a chemotherapeutic regimen based on ERCC1 expression |
| WO2002047007A2 (en) * | 2000-12-07 | 2002-06-13 | Phase It Intelligent Solutions Ag | Expert system for classification and prediction of genetic diseases |
| US7097966B2 (en) * | 2001-01-12 | 2006-08-29 | Yale University | Detection of survivin in the biological fluids of cancer patients |
| US7776518B2 (en) * | 2001-01-12 | 2010-08-17 | Yale University | Detection of survivin in the biological fluids of cancer patients |
| NZ528205A (en) * | 2001-03-12 | 2006-09-29 | Monogen Inc | Cell-based detection and differentiation of disease status in a cytological sample using a panel comprising a plurality of probes |
| US20040009489A1 (en) * | 2001-09-28 | 2004-01-15 | Golub Todd R. | Classification of lung carcinomas using gene expression analysis |
| CN1612936A (zh) * | 2001-11-09 | 2005-05-04 | 苏尔斯精细医药公司 | 利用基因表达分布图识别、监控和治疗疾病以及鉴定生物学状态 |
| US20030198972A1 (en) * | 2001-12-21 | 2003-10-23 | Erlander Mark G. | Grading of breast cancer |
-
2004
- 2004-02-05 CA CA002515096A patent/CA2515096A1/en not_active Abandoned
- 2004-02-05 WO PCT/US2004/003596 patent/WO2004071572A2/en not_active Ceased
- 2004-02-05 EP EP04708653A patent/EP1590487A2/en not_active Withdrawn
- 2004-02-05 JP JP2006503407A patent/JP2006521793A/ja active Pending
- 2004-02-05 AU AU2004211955A patent/AU2004211955B2/en not_active Ceased
- 2004-02-06 US US10/773,951 patent/US20040157255A1/en not_active Abandoned
-
2007
- 2007-05-30 US US11/755,697 patent/US20080176229A1/en not_active Abandoned
-
2009
- 2009-08-14 AU AU2009208748A patent/AU2009208748A1/en not_active Abandoned
Non-Patent Citations (3)
| Title |
|---|
| JPN6009045162, 日本癌学会総会記事，第６１巻，第１６６頁，１０５７（２００２年８月） * |
| JPN6009061797, Ｅｕｒｏｐｅａｎ Ｊｏｕｒｎａｌ ｏｆ Ｃａｎｃｅｒ, 2002, Ｖｏｌ．３８, ｐ．Ｓ４ * |
| JPN6009061798, 第５４回日本胸部外科学会総会, 2001, ｐ．３２２ * |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2017161531A (ja) * | 2007-10-19 | 2017-09-14 | セル・シグナリング・テクノロジー・インコーポレイテツド | 癌の分類および使用法 |
| WO2010064702A1 (ja) * | 2008-12-05 | 2010-06-10 | 国立大学法人 東京大学 | 癌の予後を予測するためのバイオマーカー |
| WO2010084998A1 (en) * | 2009-01-26 | 2010-07-29 | Kyushu University, National University Corporation | A method of predicting the efficacy of a drug |
| JP2014526680A (ja) * | 2011-09-12 | 2014-10-06 | ユニヴェルシテイト ヘント | 結腸直腸ガンのニューレグリン−１に基づく予後予測及び治療層別化 |
| KR20180010138A (ko) * | 2016-07-20 | 2018-01-30 | 연세대학교 산학협력단 | 암 예후 예측을 위한 조성물 및 이를 포함하는 키트 |
| KR101941054B1 (ko) | 2016-07-20 | 2019-01-23 | 연세대학교 산학협력단 | 암 예후 예측을 위한 조성물 및 이를 포함하는 키트 |
Also Published As
| Publication number | Publication date |
|---|---|
| US20040157255A1 (en) | 2004-08-12 |
| WO2004071572A3 (en) | 2005-01-13 |
| CA2515096A1 (en) | 2004-08-26 |
| WO2004071572A2 (en) | 2004-08-26 |
| AU2004211955B2 (en) | 2009-05-14 |
| AU2009208748A1 (en) | 2009-09-10 |
| EP1590487A2 (en) | 2005-11-02 |
| US20080176229A1 (en) | 2008-07-24 |
| AU2004211955A1 (en) | 2004-08-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP4606879B2 (ja) | Ｅｇｆｒ陽性癌の遺伝子発現プロファイリング | |
| AU2004211955B2 (en) | Gene expression markers for response to EGFR inhibitor drugs | |
| JP2006521793A5 (https=) | ||
| US20080318230A1 (en) | Gene expression markers for response to egfr inhibitor drugs | |
| JP4723472B2 (ja) | 乳癌予後診断のための遺伝子発現マーカー | |
| JP5486719B2 (ja) | 結腸直腸癌の予後のための遺伝子発現マーカー | |
| JP4680898B2 (ja) | 癌再発の可能性の予測 | |
| JP2006506093A5 (https=) | ||
| US20070128636A1 (en) | Predictors Of Patient Response To Treatment With EGFR Inhibitors | |
| US20120004127A1 (en) | Gene expression markers for colorectal cancer prognosis | |
| HK1148320A (en) | Gene expression markers for response to egfr inhibitor drugs |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A524 | Written submission of copy of amendment under article 19 pct |
Free format text: JAPANESE INTERMEDIATE CODE: A524 Effective date: 20070131 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20070131 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20090501 |
|
| RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7422 Effective date: 20090501 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20090713 |
|
| RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20090821 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20091130 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20100423 |